AbbVie announces SURVEYOR studies of ABT-493 & ABT-530 show high rates of sustained virologic response in patients with HCV

Press/Media: Press / Media

PeriodNov 18 2015

Media coverage

1

Media coverage

  • TitleAbbVie announces SURVEYOR studies of ABT-493 & ABT-530 show high rates of sustained virologic response in patients with HCV
    Media name/outletPharmaBiz
    CountryIndia
    Date11/18/15
    PersonsFred Poordad